Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMPL

Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis

Impel Pharmaceuticals logo

About Impel Pharmaceuticals Stock (NASDAQ:IMPL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.04
$0.84
52-Week Range
N/A
Volume
720,000 shs
Average Volume
682,655 shs
Market Capitalization
$956 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IMPL Stock News Headlines

A $674B Industry Missed the Bigger Picture
TV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.
Impel Pharmaceuticals Inc. (IMPLQ)
See More Headlines

IMPL Stock Analysis - Frequently Asked Questions

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) announced its quarterly earnings data on Monday, November, 15th. The company reported ($1.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by $0.42. The firm earned $0.09 million during the quarter.
Read the conference call transcript
.

Impel Pharmaceuticals (IMPL) raised $80 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Impel Pharmaceuticals investors own include Athenex (ATNX), NIO (NIO), KLX Energy Services (KLXE), American Airlines Group (AAL), Bolt Biotherapeutics (BOLT), Moderna (MRNA) and Novavax (NVAX).

Company Calendar

Last Earnings
11/15/2021
Today
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMPL
CIK
1445499
Fax
N/A
Employees
160
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$106.31 million
Net Margins
-353.93%
Pretax Margin
-353.93%
Return on Equity
N/A
Return on Assets
-127.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.19
Quick Ratio
0.13

Sales & Book Value

Annual Sales
$20.99 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.86) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
23,900,000
Free Float
22,418,000
Market Cap
$956 thousand
Optionable
Not Optionable
Beta
1.17
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:IMPL) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners